EAY191N4
OPEN TO ACCRUAL
Ph2 Randomized Selumetinib, Olaparib or Selumetinib in Patients w/Ovarian and Endometrial Cancer
GOG3069
OPEN TO ACCRUAL
Ph2 Study of Alpelisib & Fulvestrant for PIK3CA-mutated Estrogen Receptor Endometrial Cancers
GOG3083
OPEN TO ACCRUAL
Ph 3 Trial of Selinexor for Patients w/ p53 Wild Type, Advanced, or Recurrent Endometrial Carcinoma
GOG3104
OPEN TO ACCRUAL
Randomized Open Label Ph3 study of Sacituzumab Govitecan VS Phys Choice in Endometrial Cancer